SCHEMBL1644580

SCHEMBL1644580

Cc1cc(C)nc(OCCOc2ccc(NC(=O)C(=O)c3c(-c4ccccc4)c(C)c4ccccn34)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 3/20 0.37
PPARG P37231 3/20 0.37
NCOR2 Q9Y618 3/20 0.37
KDM4E B2RXH2 2/20 0.37
NR2E3 Q9Y5X4 2/20 0.37
PABPC1 P11940 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
PORCN Q9H237 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1645441 0.91 HCRTR1 (0.38) MAPTKMT2AMEN1ALDH1A1PPARG
SCHEMBL1645861 0.87 ALDH1A1 (0.35) MAPTKMT2AMEN1ALDH1A1PPARG
SCHEMBL1646398 0.84 SMN1; SMN2 (0.51) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL1126845 0.82 HCRTR1 (0.41) MAPTKMT2AMEN1ALDH1A1HCRTR1
SCHEMBL1645439 0.81 ALDH1A1 (0.37) MAPTKMT2AMEN1ALDH1A1PPARG
SCHEMBL1991373 0.80 HCRTR1 (0.39) MAPTKMT2AMEN1ALDH1A1KDM4E
SCHEMBL2231172 0.80 LMNA (0.43) MAPTALDH1A1KDM4EHCRTR1HCRTR2
SCHEMBL1646517 0.79 LMNA (0.36) MAPTKMT2AMEN1ALDH1A1PPARG
SCHEMBL2231282 0.79 SMN1; SMN2 (0.41) MAPTKMT2AALDH1A1KDM4EHCRTR1
SCHEMBL1645908 0.78 ALDH1A1 (0.36) MAPTKMT2AMEN1ALDH1A1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885KMT2A 3693/4885MEN1 221/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885KMT2A 1472/4885MEN1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.